ESMO 2022 | ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, describes the trial design and rationale of the Phase III ASCENT-04 trial (NCT05382286), which assesses sacituzumab govitecan, an antibody-drug conjugate (ADC), and pembrolizumab in patients with PD-L1-positive triple-negative breast cancer (TNBC). Patients are randomized to either receive the ADC with pembrolizumab or chemotherapy including paclitaxel, carboplatin or gemcitabine with pembrolizumab. Patients receiving chemotherapy may additionally crossover to receive sacituzumab govitecan if they progress. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.